Cancer research
Fresh data on pancreatic cancer have shed new light on the mechanisms driving cancer resistance to immunotherapy. A recent study published in Frontiers in Immunology has found that tumor-intrinsic interferon (IFN) signaling may contribute to pancreatic cancer cells' ability to evade treatment. Researchers at the University of North Carolina
Cancer research
Researchers at the University of Utah have made a significant breakthrough in developing a novel gene therapy for treating hepatocellular carcinoma (HCC), a type of liver cancer. The therapy, called mitochondrially targeted p53-Bad* fusion gene therapy, has shown promising results in promoting apoptosis in HCC cells by inhibiting the Bcl-2
Cancer research
Researchers at the National Cancer Center in Japan have identified common cancer antigens that can be targeted for immunotherapy in colon cancer patients, particularly those with stage IV colorectal cancer and liver metastases. According to a new report published in the International Journal of Molecular Sciences, the team analyzed expression
Cancer research
The Thyroid Cancer pipeline landscape is becoming increasingly diverse, with over 50 active players working to develop more than 50 pipeline therapies for the treatment of Thyroid Cancer. Among the prominent companies emerging in this space are AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, and AstraZeneca. These companies
Cancer research
A study published in Frontiers in Cellular and Infection Microbiology has made significant progress in understanding the relationship between the gut microbiome and immunotherapy response in lung cancer patients. Researchers at the Cancer Hospital of China Medical University conducted a comprehensive analysis of publicly available global metagenomic datasets to identify
Cancer research
The Yonsei University Health System's Gangnam Severance Hospital in South Korea has conducted a clinical trial to investigate the efficacy of early post-operative rehabilitation in patients with thyroid cancer who underwent transaxillary robot-assisted surgery. The primary objective of the study is to determine whether early patient education and
Cancer research
DelveInsight's report, "Recurrent or Metastatic Head and Neck Cancer Pipeline Insight 2025", provides a comprehensive analysis of the pipeline landscape for this devastating disease. As of August 2025, 40+ companies and 40+ pipeline drugs are actively being developed to treat recurrent or metastatic head and neck
Cancer research
Researchers from Sichuan University in Chengdu, People's Republic of China, have developed and evaluated a radiomics-based machine learning model to differentiate between lung squamous cell carcinoma (SCC) and adenocarcinoma (AC) in patients with brain metastases (BMs). The study used T1-enhanced magnetic resonance imaging (MRI) features and identified 833
Cancer research
Researchers from the Petru Poni Institute of Macromolecular Chemistry in Romania have made a significant discovery in the field of cancer gene therapy. They have developed a dual-functional nanoplatform, named carbon dot-enhanced doxorubicin liposomes, which has shown remarkable synergistic antitumor activity. This innovative approach combines the therapeutic effects of doxorubicin,
Cancer research
Researchers from Monash University have successfully demonstrated the feasibility of high-energy propagation-based computed tomography for human adult-scale lung imaging using the Australian Synchrotron's Imaging and Medical Beamline. This novel technique offers a significant advancement in medical imaging, allowing for lower radiation doses and improved diagnostic accuracy for lung
Cancer research
Researchers from King Abdulaziz University have made a significant discovery regarding the potential of propranolol as an adjuvant therapy for colorectal cancer. According to their study, which was published in the International Journal of Molecular Sciences, propranolol suppressed cell proliferation, altered cell morphology, and induced apoptosis in a panel of
Cancer research
The Advanced Kidney Cancer pipeline landscape is marked by 50+ companies and 55+ pipeline drugs, with a majority of these therapies in various stages of clinical trials. AstraZeneca's Savolitinib and Bristol-Myers Squibb's Relatlimab are among the notable pipeline drugs for Advanced Kidney Cancer treatment. The pipeline
